With Ver­tex and CRISPR some 30 pa­tients in, Ed­i­tas moves for­ward in sick­le cell pa­tients af­ter FDA lifts hold

With gene ther­a­pies for sick­le cell dis­ease prov­ing all the rage, one com­pa­ny is get­ting its FDA-im­posed chains re­moved.

Ed­i­tas Med­i­cine an­nounced Wednes­day that the …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER